Zacks Investment Research upgraded shares of Hill-Rom Holdings Inc (NYSE:HRC) from a sell rating to a hold rating in a research note issued to investors on Tuesday.

According to Zacks, “Over the last three months, Hill-Rom has been underperforming the broader industry. Moreover, it exited the last reported quarter on a mixed note with earnings ahead of estimates but revenues missing the same. Also, decrease in Patient Support Systems revenues was disappointing. Moreover, a decline in reported gross margin was dampening. Also, lowered full year guidance suggests dull prospects ahead. On a positive note, Hill-Rom saw a solid year-over-year increase in revenues on strong international growth. Hill-Rom currently aims to gain traction in the untapped international market on successful execution. The company is focusing on product innovation through research and development. Also, its launches slated for the fourth quarter are pumping up investors’ confidence. With regard to this, the commercial launch of its Centrella Med-Surg platform is worth a mention.”

HRC has been the topic of several other research reports. BidaskClub lowered shares of Hill-Rom Holdings from a strong-buy rating to a buy rating in a research note on Monday, July 24th. Morgan Stanley boosted their price objective on shares of Hill-Rom Holdings from $85.00 to $90.00 and gave the stock an overweight rating in a research note on Friday, June 30th. Stifel Nicolaus reissued a buy rating and set a $84.00 price objective on shares of Hill-Rom Holdings in a research note on Sunday, July 30th. Cantor Fitzgerald set a $86.00 price objective on shares of Hill-Rom Holdings and gave the stock a hold rating in a research note on Friday, July 28th. Finally, Barclays PLC boosted their price objective on shares of Hill-Rom Holdings from $80.00 to $86.00 and gave the stock an overweight rating in a research note on Friday, June 9th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $87.80.

Hill-Rom Holdings (HRC) traded down 0.08% during midday trading on Tuesday, hitting $77.57. 225,456 shares of the company were exchanged. Hill-Rom Holdings has a 1-year low of $50.50 and a 1-year high of $84.65. The stock has a 50 day moving average of $75.22 and a 200 day moving average of $75.84. The firm has a market capitalization of $5.11 billion, a PE ratio of 45.20 and a beta of 1.19.

Hill-Rom Holdings (NYSE:HRC) last posted its quarterly earnings data on Friday, July 28th. The medical technology company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.90 by $0.01. Hill-Rom Holdings had a net margin of 4.27% and a return on equity of 19.99%. The business had revenue of $689.10 million for the quarter, compared to analyst estimates of $695.50 million. During the same quarter in the previous year, the firm posted $0.81 earnings per share. Hill-Rom Holdings’s quarterly revenue was up 5.1% on a year-over-year basis. On average, equities analysts predict that Hill-Rom Holdings will post $3.82 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Hill-Rom Holdings Inc (HRC) Raised to “Hold” at Zacks Investment Research” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.watchlistnews.com/hill-rom-holdings-inc-hrc-raised-to-hold-at-zacks-investment-research/1613416.html.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 15th were paid a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a yield of 0.93%. The ex-dividend date was Thursday, September 14th. Hill-Rom Holdings’s payout ratio is currently 41.62%.

In other news, SVP Andreas G. Frank sold 3,940 shares of the company’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $77.84, for a total value of $306,689.60. Following the transaction, the senior vice president now owns 16,701 shares in the company, valued at $1,300,005.84. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Andreas G. Frank sold 6,870 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $77.48, for a total transaction of $532,287.60. Following the completion of the transaction, the senior vice president now owns 16,701 shares in the company, valued at approximately $1,293,993.48. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Canada Pension Plan Investment Board lifted its stake in shares of Hill-Rom Holdings by 42.7% in the second quarter. Canada Pension Plan Investment Board now owns 16,700 shares of the medical technology company’s stock worth $1,329,000 after buying an additional 5,000 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Hill-Rom Holdings by 1,191.1% in the second quarter. American Century Companies Inc. now owns 110,359 shares of the medical technology company’s stock worth $8,786,000 after buying an additional 101,811 shares in the last quarter. Brookstone Capital Management bought a new position in shares of Hill-Rom Holdings in the second quarter worth approximately $289,000. Chase Investment Counsel Corp bought a new position in shares of Hill-Rom Holdings in the second quarter worth approximately $675,000. Finally, Prudential Financial Inc. lifted its stake in shares of Hill-Rom Holdings by 6.6% in the second quarter. Prudential Financial Inc. now owns 545,786 shares of the medical technology company’s stock worth $43,449,000 after buying an additional 33,714 shares in the last quarter. Hedge funds and other institutional investors own 82.31% of the company’s stock.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Get a free copy of the Zacks research report on Hill-Rom Holdings (HRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Hill-Rom Holdings (NYSE:HRC)

Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.